SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Vixtimotamab

Cat. No.: HY-P99958

Target: Others

Pathway: Others

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML)[1].

IC_{50} & Target

KD: 0.3 nM (CD33, HL-60 cells), 5.1 nM (CD3, Human T cells)[1]

In Vitro

Vixtimotamab (TandAb T564; 24 h) induces CD25 and CD69 with EC_{50}s of 1 pM and 2 pM, respectively[1].
Vixtimotamab (TandAb T564; 4 days) induces T-cell proliferation in PBMCs with an EC_{50} of 3 pM[1].
Vixtimotamab (TandAb T564; 25 pM, 48 h) shows cytotoxicity against HL-60 and KG-1a cells[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay[1]

Cell Line:	HL-60 and KG-1a cells
Concentration:	25 pM
Incubation Time:	48 h
Result:	Showed cytotoxicity of 86.0±1.4% and 81.3±1.5% against HL-60 and KG-1a cells, respectively.

In Vivo

Vixtimotamab (TandAb T564; 0.1-10 μg/mouse, i.v.; 5 days) demonstrates dose-dependent tumor growth delay in a prophylactic HL-60 graft NOD/scid mouse model[1].
Vixtimotamab (TandAb T564; 50 μg/mouse/d, i.v.; 7 days) substantially inhibits tumor growth in an established HL-60 xenograft NOD/scid mouse model[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	8-week-old NOD/scid female mice, weighing 20.7 ± 1.48 g, prophylactic HL-60 graft model [1]
Dosage:	0.1, 1, or 10 μg/mouse
Administration:	Intravenous injection, on days 0, 1, 2, 3, and 4

Result:	Demonstrated dose-dependent tumor growth delay.

REFERENCES

[1]. Reusch U, et al. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia. Clin Cancer Res. 2016 Dec 1;22(23):5829-5838.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA